ArticleNeoplasia (New York, N.Y.)2008
Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations.
Article in Neoplasia (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 72 citations in OpenAlex.
- NPEPPS Is a Druggable Driver of Platinum Resistance.Cancer research · 2024Article
- Tumor collagens predict genetic features and patient outcomes.NPJ genomic medicine · 2023Article
- Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?Cancer reports (Hoboken, N.J.) · 2021Article
- Experimental and bioinformatics considerations in cancer application of single cell genomics.Computational and structural biotechnology journal · 2021Article
- Advances in urinary biomarker discovery in urological research.Investigative and clinical urology · 2020Review
- FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.BMC cancer · 2019Article
- Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.Cancer reports (Hoboken, N.J.) · 2018Article
- Diagnostic and Prognostic Implications of FGFR3International journal of molecular sciences · 2018Article
- Review
- Expression of FGFR3 Protein and Gene Amplification in Urinary Bladder Lesions in Relation to Schistosomiasis.Open access Macedonian journal of medical sciences · 2017Article
- Improving Systemic Chemotherapy for Bladder Cancer.Current oncology reports · 2016Review
- Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.European journal of pharmacology · 2015Article
- Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Article
- Clinical and pathological implications of miRNA in bladder cancer.International journal of nanomedicine · 2015Review
- Comparison of structural genetics of non-schistosoma-associated squamous cell carcinoma of the urinary bladder.International journal of clinical and experimental pathology · 2015Article
- Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer.Oncology letters · 2014Article
- Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA.Journal of translational medicine · 2013Article
- Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- A noninvasive multi-analyte diagnostic assay: combining protein and DNA markers to stratify bladder cancer patients.Research and reports in urology · 2012Article
- Detection of low frequency FGFR3 mutations in the urine of bladder cancer patients using next-generation deep sequencing.Research and reports in urology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to analyze the distribution of FGFR3 mutations in bladder tumors of different grade and stage and determine the relation of mutations to chromosomal alterations detected by comparative genomic hybridization (CGH). One hundred bladder cancer samples served as templates for manual microdissection. DNA was isolated from dissected samples containing at least 80% tumor cells. Mutations in FGFR3 were analyzed by SNaPshot analysis. CGH was carried out according to standard protocols. FGFR3 mutations were detected in 45 of 92 samples (48.9%). Concerning T-category, the following mutation frequencies occurred: pTa, 69%; pT1, 38%; and pT2-3, 0%. The mutation frequency was significantly associated with tumor grade: G1, 72%; G2, 56%; and G3, 4%. In pTaG1 tumors, mutations were found in 74%. A significantly lower number of genetic alterations per tumor detected by CGH was associated with FGFR3 mutations (2 vs 8). This association was also seen in pTaG1 tumors: 2.5 (with mutation) vs 7.5 (without mutation). FGFR3 mutations characterize noninvasive low-risk tumors of low malignancy. The low malignant potential of these tumors is underlined by a low number of genetic alterations per tumor. Therefore, FGFR3 represents a valuable prognostic marker of tumors with low malignant potential and can be used as surrogate marker for the detection of genetically stable bladder tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.